The Pfizer is seeking applications for its Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool.
Donor Name: Pfizer
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 05/05/2026
Size of the Grant: $100,000 to $500,000
Grant Duration: 1 Year
Details:
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive, life threatening condition associated with significant morbidity, mortality, and burden on patients, caregivers, and healthcare systems. The multi-systemic disease course is often characterized by diagnostic delays, complex treatment pathways, and evolving therapeutic options, which can create uncertainty and decisional conflict for patients and clinicians alike.
Shared decision-making (SDM) has emerged as a critical component of patient centered care, particularly in complex and preference-sensitive conditions such as ATTR-CM. Well-designed decision aids can support meaningful dialogue between patients and healthcare professionals by improving understanding of disease trajectory, treatment options, risks and benefits, and alignment of care with individual patient values and goals.
Project Types and Area of Interest
This RFP seeks to support medical societies or professional organizations, in partnership with patient advocacy organizations, to develop, validate, and/or evaluate a shared decision-making tool (Decision Aid) aimed at improving decision quality, health outcomes, patient experience, and quality of care among individuals living with ATTR-CM.
Funding Information
One individual project requesting up to $250,000 USD will be considered. Maximum project length is 1 year.
Geographic Scope
United States
Eligibility Criteria
- Medical societies or professional organizations, in partnership with patient advocacy organizations, that include transthyretin cardiac amyloidosis (ATTR-CM) as one of the focus areas are encouraged to apply.
- The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. They strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
For more information, visit Pfizer.
